154992-24-2
154992-24-2
Chemical Structure
RU 58841
Synonym(s): PSK-3841; HMR-3841
- CAS No.: 154992-24-2
- Formula:C17H18F3N3O3
- Molecular Weight:369.34
IUPAC Name: 4-(3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile
InChIKey: ARBYGDBJECGMGA-UHFFFAOYSA-N
SMILES: FC(F)(C1=C(C=CC(N2C(C(C)(N(C2=O)CCCCO)C)=O)=C1)C#N)F
Biological Activity: RU 58841 (PSK-3841) is a specific androgen receptor antagonist or anti-androgen. RU 58841 has a dramatic effect on hair regrowth[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RU 58841 | 99.72% | RU 58841 (PSK-3841) is a specific androgen receptor antagonist or anti-androgen. RU 58841 has a dramatic effect on hair regrowth. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RU 58841 (Standard) | ≥98% | RU 58841 (Standard) is the analytical standard of RU 58841 (HY-10561). This product is intended for research and analytical applications. RU 58841 (PSK-3841) is a specific androgen receptor antagonist or anti-androgen. RU 58841 has a dramatic effect on hair regrowth. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CH4933468 | CH4933468 is a thiohydantoin derivative, shows androgen receptor (AR) pure antagonist activity in vitro. CH4933468 inhibits AR-mediated transactivation and proliferation of LNCaP and LNCaP-BC2 cells. CH4933468 can be used for castration-resistant prostate cancer (CRPC) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Androgen receptor antagonist 9 | 99.91% | Androgen receptor antagonist 9 (compound 28) is an antagonist of the androgen receptor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RU 56187 | RU 56187 is an active compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RU 59063 | 98.61% | RU 59063 is a high-affinity, selective nonsteroidal androgen receptor (AR) ligand that acts as a partial AR agonist/antagonist in CV-1 cell transcription assays. RU 59063 has a Ka value of 6.2×109 M-1 for human AR. RU 59063 induces a conformation of AR that can bind to the androgen response element (ARE), triggers partial AR-dependent transcriptional activation, and antagonizes testosterone-induced AR transcriptional activity. RU 59063 inhibits testosterone propionate-induced ornithine decarboxylase activity in mouse kidneys and testosterone propionate-induced prostate weight gain in rats. RU 59063 can be used in studies related to prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RU 58642 | RU 58642 is an orally active non-steroidal antiandrogen, which displays a strong and selective affinity for androgen receptor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PROTAC AR/AR-V7 degrader-1 | 99.72% | PROTAC AR/AR-V7 degrader-1 (27c) is a PROTAC-based and dual AR, AR-V7 degrader, with DC50 values of 2.67 and 2.64 μM for AR and AR-V7, respectively. PROTAC AR/AR-V7 degrader-1 (27c) induces apoptosis (Red: AR antagonist; Blue: E3 ligase ligand; Black: linker). |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GLPG0492 | 99.85% | GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GLPG0492 (R enantiomer) | 99.51% | GLPG0492 R enantiomer is the R enantiomer of GLPG0492. GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RU 56279 | RU 56279 is an androgen receptor (AR) antagonist with strong and systemic anti-androgenic activity. RU 56279 is also a common, potent and long-lasting anti-androgen metabolite of RU 56187 (HY-117486) and RU 58841 (HY-10561) in vivo. RU 56279 can be used as an AR ligand to construct an AR-targeted prodrug system for the study of AR-positive tumor cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ro 13-3978 | Ro 13-3978 is an orally active antischistosomal agent. Ro 13-3978 exhibits excellent in vivo antischistosomal activity against juvenile and adult Schistosoma mansoni infections. Ro 13-3978 shows no in vivo activity against E. caproni and F. hepatica. Ro 13-3978 blocks dihydrotestosterone-induced proliferation of androgen-dependent cells. Ro 13-3978 can be used in research related to schistosomiasis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice By De Brouwer, B.; Tetelin, C.; Leroy, T.; Bonfils, A.; Van Neste, D. .From British Journal of Dermatology (1997), 137(5), 699-702. [Content Brief]
- [2]. Münster U, Nakamura C, Haberland A, Jores K, Mehnert W, Rummel S, Schaller M, Korting HC, Zouboulis ChC, Blume-Peytavi U, Sch?fer-Korting M.RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia.Pharmazie. 2005 Jan;60(1):8-12. [Content Brief]
- [3]. Battmann T, Bonfils A, Branche C, Humbert J, Goubet F, Teutsch G, Philibert D.RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism.J Steroid Biochem Mol Biol. 1994 Jan;48(1):55-60. [Content Brief]
